18588-50-6

Basic information

• Product Name: 6-Methyl-5-phenyl-2,4-pyrimidinediamine
• Synonyms: 6-Methyl-5-phenyl-2,4-pyrimidinediamine
• CAS NO: 18588-50-6
• Molecular Formula: C₁₁H₁₂N₄
• Molecular Weight: 200.27
• Mol File: 18588-50-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 327.97°C (rough estimate)
• Flash Point: 244.9°C
• Appearance: /
• Density: 1.2007 (rough estimate)
• Vapor Pressure: 1.16E-07mmHg at 25°C
• Refractive Index: 1.4260 (estimate)
• CAS DataBase Reference: 6-Methyl-5-phenyl-2,4-pyrimidinediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Methyl-5-phenyl-2,4-pyrimidinediamine(18588-50-6)
• EPA Substance Registry System: 6-Methyl-5-phenyl-2,4-pyrimidinediamine(18588-50-6)

Safety Data

• Hazardous Substances Data: 18588-50-6(Hazardous Substances Data)

Usage

General Description

6-Methyl-5-phenyl-2,4-pyrimidinediamine, also known as MX-1938, is a chemical compound with potential pharmaceutical applications. It belongs to the class of pyrimidine derivatives and is known for its inhibitory effects on certain enzymes. MX-1938 has been investigated for its potential use in the treatment of various diseases, including cancer and neurodegenerative disorders. Research has shown that this compound has the ability to selectively inhibit specific enzyme targets, making it a promising candidate for the development of novel therapeutic agents. Its unique chemical structure and potential biological activity make MX-1938 an interesting subject for further research and development in the pharmaceutical industry.

InChI:InChI=1/C11H12N4/c1-7-9(8-5-3-2-4-6-8)10(12)15-11(13)14-7/h2-6H,1H3,(H4,12,13,14,15)

Upstream product

• 186581-53-3 diazomethane 
• 4468-48-8 1-phenyl-1-cyanopropan-2-one 
• 50-01-1 guanidine hydrochloride 
• 22211-32-1 3-Methoxy-2-phenyl-cis-crotononitril 
• 113-00-8 guanidine nitrate 
• 506-93-4 guanidine nitrate 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES

A method of treating a lysosomal storage disease comprises administering a pyrimethamine derivative to a subject in need thereof.

Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine resistant Plasmodium falciparum

The reduced binding of pyrimethamine to Serl08Asn (S108N) mutants of parasite dihydrofolate reductase (DHFR), which forms the basis of resistance of Plasmodium falciparum to pyrimethamine, is largely due to steric constraint imposed by the bulky side chain of N108 on Cl of the 5-p-Cl-phenyl group. This and other S108 mutants with bulky side chains all showed reduced binding to pyrimethamine and cycloguanil. Less effect on binding to some bulky mutants was observed for trimethoprim, with greater flexibility for the 5-substituent. S108N DHFR also binds poorly with other pyrimethamine derivatives with bulky groups in place of the p-Cl, and the binding was generally progressively poorer for the double (C59R+S108N) mutant. Removal of the p-Cl or replacement with m-Cl led to better binding with the mutant DHFRs. Pyrimethamine analogues with unbranched hydrophobic 6-substituents showed generally good binding with the mutant DHFRs. A number of compounds were identified with high affinities for both wild-type and mutant DHFRs, with very low to no affinity to human DHFR. Some of these compounds show good antimalarial activities against pyrimethamine-resistant P. falciparum containing the mutant DHFRs with low cytotoxicity to three mammalian cell lines.